CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 28 enrolled
Drug / intervention
human retinal progenitor cellsbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02320812
NCT02320812Phase 2Completed
CompareCT.gov

A Prospective, Multicenter, Open-Label, Single-Arm Study of the Safety and Tolerability of a Single, Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects With Retinitis Pigmentosa (RP)

jCyte, Inc·interventional·Posted Dec 19, 2014·Updated Mar 5, 2019

In Brief

A Phase 2 clinical trial evaluating human retinal progenitor cells for Retinitis Pigmentosa (RP). Completed, enrolled 28 participants across 2 sites.

Detailed Summary

This study evaluates the safety and potential activity of a single dose of live human retinal progenitor cells (jCell) administered to adults with retinitis pigmentosa. Four different dose levels of cells will be assessed in each of two groups of patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRetinitis Pigmentosa (RP)
CountriesUnited States
CollaboratorsCalifornia Institute for Regenerative Medicine (CIRM)

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 19, 2014
Enrollment StartJun 1, 2015
Primary CompletionJul 19, 2017
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 11.5 years ago

Interventions

human retinal progenitor cellsbiological

single intravitreal injection of 0.5 - 3.0 million human retinal progenitor cells (hRPC)